Heparin-binding Properties of the Amyloidogenic Peptides Aβ and Amylin (1997)

Aggregation and deposition of the 40–42-residue amyloid β-protein (Aβ) are early and necessary neuropathological events in Alzheimer's disease. An understanding of the molecular interactions that trigger these events is important for therapeutic strategies aimed at blocking Aβ plaque formation at the earliest stages. Heparan sulfate proteoglycans may play a fundamental role since they are invariably associated with Aβ and other amyloid deposits at all stages. However, the nature of the Aβ-heparan sulfate proteoglycan binding has been difficult to elucidate because of the strong tendency of Aβ to self-aggregate. Affinity co-electrophoresis can measure the binding of proteoglycans or glycosaminoglycans to proteins without altering the physical state of the protein during the assay. We used affinity co-electrophoresis to study the interaction between Aβ and the glycosaminoglycan heparin and found that the aggregation state of Aβ governs its heparin-binding properties: heparin binds to fibrillar but not nonfibrillar Aβ. The amyloid binding dye, Congo red, inhibited the interaction in a specific and dose-dependent manner. The “Dutch” mutant AβE22Q peptide formed fibrils more readily than wild type Aβ and it also attained a heparin-binding state more readily, but, once formed, mutant and wild type fibrils bound heparin with similar affinities. The heparin-binding ability of aggregated AβE22Q was reversible with incubation in a solvent that promotes α-helical conformation, further suggesting that conformation of the peptide is important. Studies with another human amyloidogenic protein, amylin, suggested that its heparin-binding properties were also dependent on aggregation state. These results demonstrate the dependence of the Aβ-heparin interaction on the conformation and aggregation state of Aβ rather than primary sequence alone, and suggest methods of interfering with this association. Aggregation and deposition of the 40–42-residue amyloid β-protein (Aβ) are early and necessary neuropathological events in Alzheimer's disease. An understanding of the molecular interactions that trigger these events is important for therapeutic strategies aimed at blocking Aβ plaque formation at the earliest stages. Heparan sulfate proteoglycans may play a fundamental role since they are invariably associated with Aβ and other amyloid deposits at all stages. However, the nature of the Aβ-heparan sulfate proteoglycan binding has been difficult to elucidate because of the strong tendency of Aβ to self-aggregate. Affinity co-electrophoresis can measure the binding of proteoglycans or glycosaminoglycans to proteins without altering the physical state of the protein during the assay. We used affinity co-electrophoresis to study the interaction between Aβ and the glycosaminoglycan heparin and found that the aggregation state of Aβ governs its heparin-binding properties: heparin binds to fibrillar but not nonfibrillar Aβ. The amyloid binding dye, Congo red, inhibited the interaction in a specific and dose-dependent manner. The “Dutch” mutant AβE22Q peptide formed fibrils more readily than wild type Aβ and it also attained a heparin-binding state more readily, but, once formed, mutant and wild type fibrils bound heparin with similar affinities. The heparin-binding ability of aggregated AβE22Q was reversible with incubation in a solvent that promotes α-helical conformation, further suggesting that conformation of the peptide is important. Studies with another human amyloidogenic protein, amylin, suggested that its heparin-binding properties were also dependent on aggregation state. These results demonstrate the dependence of the Aβ-heparin interaction on the conformation and aggregation state of Aβ rather than primary sequence alone, and suggest methods of interfering with this association. A hallmark of both Alzheimer's disease (AD) 1The abbreviations used are: AD, Alzheimer's disease; Aβ, amyloid β-peptide; HSPG, heparan sulfate proteoglycan; ACE, affinity co-electrophoresis; HCHWA-D, Hereditary Cerebral Hemorrhage with Amyloidosis, Dutch-type; HPLC, high performance liquid chromatography; CSF, cerebrospinal fluid; NaMOPSO, 3-[N-morpholino]-2-hydroxypropanesulfonic acid, sodium salt; LMW, low molecular weight; HFIP, (1,1,1,3,3,3)-hexafluoroisopropanol. and Down's syndrome is the presence of numerous extracellular deposits of the amyloid β-protein (Aβ), termed senile or neuritic plaques, in the brain parenchyma. In most cases, Aβ is also deposited in the walls of parenchymal and meningeal blood vessels. In these two types of deposits, Aβ exists largely in a fibrillar form consisting of 40 or 42 amino acid monomers aggregated into insoluble filamentous polymers. Aβ, which is derived by endoproteolysis from the β-amyloid precursor protein (1Kang J. Lemaire H.-G. Unterbeck A. Salbaum J.M. Masters C.L. Greschik K.-H. Multhaup G. Beyreuther K. Müller-Hill B. Nature. 1987; 325: 733-736Crossref PubMed Scopus (3968) Google Scholar, 2Haass C. Schlossmacher M.G. Hung A.Y. Vigo-Pelfrey C. Mellon A. Ostaszewski B.L. Lieberburg I. Koo E.H. Schenk D. Teplow D.B. Selkoe D.J. Nature. 1992; 359: 322-325Crossref PubMed Scopus (1767) Google Scholar), is by far the major constituent of plaques (3Masters C.L. Simms G. Weinman N.A. Multhaup G. McDonald B.L. Beyreuther K. Proc. Natl. Acad. Sci. U. S. A. 1985; 82: 4245-4249Crossref PubMed Scopus (3699) Google Scholar, 4Selkoe D.J. Abraham C.R. Podlisny M.B. Duffy L.K. J. Neurochem. 1986; 146: 1820-1834Google Scholar, 5Roher A. Wolfe D. Palutke M. KuKuruga D. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 2662-2666Crossref PubMed Scopus (122) Google Scholar). However, several other plaque-associated proteins have been described, including α1-antichymotrypsin (6Abraham C.R. Selkoe D.J. Potter H. Cell. 1988; 52: 487-501Abstract Full Text PDF PubMed Scopus (804) Google Scholar), apolipoprotein E (7Namba Y. Tomonaga M. Kawasaki H. Otomo E. Ikeda K. Brain Res. 1991; 541: 163-166Crossref PubMed Scopus (1023) Google Scholar), the heparan sulfate proteoglycan (HSPG) perlecan (8Snow A.D. Mar H. Hochlin D. Kimata K. Kato M. Suzuki S. Hassell J. Wight T.N. Am. J. Pathol. 1988; 133: 456-463PubMed Google Scholar), serum amyloid P component (9Coria F. Castano E. Prelli F. Larrondo-Lillo M. van Duinen S. Shelanski M.L. Frangione B. Lab. Invest. 1988; 58: 454-458PubMed Google Scholar), and complement factors (10Eikelenboom P. Stam F.C. Acta Neuropathol. 1982; 57: 239-242Crossref PubMed Scopus (387) Google Scholar). The order in which these various proteinaceous components are added to the senile plaques is not well understood, but some clues can be obtained from the composition of another type of Aβ deposit found in AD brains. “Diffuse” plaques are composed of Aβ in a particulate but not fibrillar form and do not react with the classic amyloid-staining dyes, Congo red and thioflavin S. Because the brains of young (<30 year old) Down's syndrome patients almost exclusively contain diffuse plaques, these deposits are believed to be the precursors of the compacted amyloid plaques, which invariably develop in older (>30–40 year old) Down's syndrome subjects (11Mann D.M.A. Brown A. Prinja D. Davies C.A. Landon M. Masters C.L. Beyreuther K. Neuropathol. Appl. Neurobiol. 1989; 15: 317-329Crossref PubMed Scopus (64) Google Scholar, 12Lemere C.A. Blusztajn J.K. Yamaguchi H. Wisniewski T. Saido T.C. Selkoe D.J. Neurobiol. Dis. 1996; 3: 16-32Crossref PubMed Scopus (467) Google Scholar). Snow and colleagues (8Snow A.D. Mar H. Hochlin D. Kimata K. Kato M. Suzuki S. Hassell J. Wight T.N. Am. J. Pathol. 1988; 133: 456-463PubMed Google Scholar, 13Snow A.D. Mar H. Nochlin D. Sekiguchi R.T. Kimata K. Koike Y. Wight T.N. Am. J. Pathol. 1990; 137: 1253-1270PubMed Google Scholar) have detected immunohistochemically the presence of a specific HSPG, perlecan, in the compacted plaques and cerebrovascular amyloid of Alzheimer's disease brain. In addition, diffuse plaques in the hippocampus and cerebral cortex, but not in the cerebellum, were shown to contain perlecan (13Snow A.D. Mar H. Nochlin D. Sekiguchi R.T. Kimata K. Koike Y. Wight T.N. Am. J. Pathol. 1990; 137: 1253-1270PubMed Google Scholar, 14Snow A.D. Sekiguchi R.T. Nochlin D. Kalaria R.N. Kimata K. Am. J. Pathol. 1994; 144: 337-347PubMed Google Scholar). Because compacted plaques are rarely found in the cerebellum even in end stage AD brains (15Joachim C.L. Morris J.H. Selkoe D.J. Am. J. Pathol. 1989; 135: 309-319PubMed Google Scholar), it is postulated that HSPGs such as perlecan could play a role in the transition of diffuse Aβ deposits into compacted amyloid. The finding that cortical diffuse plaques in Down's syndrome brain are also perlecan-immunoreactive (13Snow A.D. Mar H. Nochlin D. Sekiguchi R.T. Kimata K. Koike Y. Wight T.N. Am. J. Pathol. 1990; 137: 1253-1270PubMed Google Scholar) is consistent with this hypothesis. HSPGs may play a general role in the formation and stabilization of many types of amyloid, since they have also been identified in association with amyloid deposits in virtually all other human amyloid diseases (for review, see Ref. 16Snow A.D. Wight T.N. Neurobiol. Aging. 1989; 10: 481-497Crossref PubMed Scopus (188) Google Scholar). In AD cerebrovasculature, Aβ amyloid deposits have been ultrastructurally localized to the vascular basement membrane region of capillaries, arterioles, and small arteries (17Yamaguchi H. Yamazaki T. Lemere C.A. Frosch M.P. Selkoe D.J. Am. J. Pathol. 1992; 141: 249-259PubMed Google Scholar), where perlecan is a prominent constituent. In addition, one of the diseases linked genetically to β-amyloid precursor protein (Hereditary Cerebral Hemorrhage with Amyloidosis, Dutch-type (HCHWA-D)) causes a particularly severe deposition of Aβ in meningocerebral blood vessels (18Luyendijk W. Bots G.T.A.M. Vegter-van der Vlis M. Went L.N. Frangione B. J. Neurol. Sci. 1988; 85: 267-280Abstract Full Text PDF PubMed Scopus (97) Google Scholar, 19Levy E. Carman M.D. Fernandez-Madrid I.J. Power M.D. Lieberburg I. van Duinen S.G. Bots G.T.A.M. Luyendijk W. Frangione B. Science. 1990; 248: 1124-1126Crossref PubMed Scopus (1167) Google Scholar), again suggesting an important role for a vascular basement membrane factor in Aβ deposition. Previous attempts to characterize the binding between HSPGs and Aβ (20Brunden K.R. Richter-Cook N.J. Chaturvedi N. Frederickson R.C.A. J. Neurochem. 1993; 61: 2147-2154Crossref PubMed Scopus (121) Google Scholar, 21Buée L. Ding W. Delacourte A. Fillit H. Brain Res. 1993; 601: 154-163Crossref PubMed Scopus (76) Google Scholar, 22Buée L. Ding W. Anderson J.P. Narindrasorasak S. Kisilevsky R. Boyle N.J. Robakis N.K. Delacourte A. Greenberg B. Fillit H.M. Brain Res. 1993; 627: 199-204Crossref PubMed Scopus (67) Google Scholar, 23Snow A.D. Kinsella M.G. Parks E. Sekiguchi R.T. Miller J.D. Kimata K. Wight T.N. Arch. Biochem. Biophys. 1995; 320: 84-95Crossref PubMed Scopus (126) Google Scholar) have been hindered by the unique difficulties of working with synthetic Aβ, a highly hydrophobic 40–42-amino acid peptide that readily precipitates into insoluble aggregates in vitro. Affinity co-electrophoresis (ACE) is an advantageous method to characterize the binding of proteins to proteoglycans or their glycosaminoglycan side A.D. Proc. Natl. Acad. Sci. U. S. A. 1991; PubMed Scopus Google Scholar, A.D. P. A to Scholar). component is a highly and of component to or is all of the binding Aβ has to during the than in many other types of binding In this to characterize the binding of Aβ to heparin glycosaminoglycan that is used as a for heparan at and wild type Aβ and the mutant form were We that the interaction is dependent on the and aggregation state of Aβ and is inhibited by the Congo Aβ the binds heparin more readily than wild type peptide to its tendency to form not because of a affinity for demonstrate that another human amylin, also binds to the and of type peptide was and by D. Teplow and the “Dutch” was by D. of and were by D. and and were from or The amino acid sequence of wild type human is Ref. J. Lemaire H.-G. Unterbeck A. Salbaum J.M. Masters C.L. Greschik K.-H. Multhaup G. Beyreuther K. Müller-Hill B. Nature. 1987; 325: 733-736Crossref PubMed Scopus (3968) Google in mutant is to E. Carman M.D. Fernandez-Madrid I.J. Power M.D. Lieberburg I. van Duinen S.G. Bots G.T.A.M. Luyendijk W. Frangione B. Science. 1990; 248: 1124-1126Crossref PubMed Scopus (1167) Google Scholar). and nonfibrillar Aβ were in at and used fibrillar Aβ was formed by the peptide in to cerebrospinal in to a of Aβ peptide and it for at by at The was in in Ref. A.D. Proc. Natl. Acad. Sci. U. S. A. 1991; PubMed Scopus Google Scholar) and A similar an of formation at T. E. J. Frangione B. Neurol. 1993; PubMed Scopus Google Scholar). of peptide were and the peptide were by amino acid by M. and of peptide were to a with and with a at Congo red was by the of Prelli F. Wisniewski T. A. C. Frangione B. Biochem. J. 1995; PubMed Scopus Google Scholar). was added to the of heparin a J.D. J. J. A.D. 1993; PubMed Scopus Google Scholar). method heparin and not the of the heparin its The was by the method and the heparin was by The low molecular was used to the of binding heparin was from were with two as A.D. Proc. Natl. Acad. Sci. U. S. A. 1991; PubMed Scopus Google Scholar, A.D. P. A to Scholar), a of and a of peptide were in and with an of into the and to The was which was to the the the of were a and the with that Aβ not from its during the used of a was where is the of heparin is a protein Ref. A.D. Proc. Natl. Acad. Sci. U. S. A. 1991; PubMed Scopus Google Scholar). were to the A.D. P. A to Scholar). In were obtained with suggesting in or the that some Aβ fibrils are on the walls of and in the of Aβ to be at the are in of of and were by amino acid for were these of a on the of fibrils a of fibrillar or nonfibrillar Aβ were for at in In some cases, of Congo red or of were these were for The were to by a by one with The was and the bound on the was in a in were from the for from Aβ and heparin were to a for Aβ-heparin to measure the binding of Aβ to heparin were of wild type were in and were into the of a and was to the of Aβ is than that of heparin not a of heparin and Aβ to have a than that of this is the binding of Aβ to heparin have been as a of that were with Aβ In of Aβ on heparin was at peptide to These that Aβ and heparin do not the of the or that binding could not be detected because the of the Aβ-heparin is not from that of heparin the the of heparin and peptide in the A.D. P. A to Scholar). In this heparin was into the into a to the Because heparin is more than Aβ, the was between the heparin and the In this binding of heparin to Aβ have been as a of was by heparin However, as shown in in the of was at heparin to the could have to binding of heparin and Aβ in this is the of the was not from that of the in this Aβ. However, it is not for the of the to be from both that of Aβ and that of as Aβ and heparin have that are from the results in A and that Aβ and heparin do not other Because the association of heparan sulfate with Aβ deposits in AD brain suggested an important interaction between the two the that the of fibrillar Aβ a heparin-binding Aβ into of were in and into and for at of the the formation of in similar to the and of Aβ fibrils from Alzheimer's plaques J. Neuropathol. Neurol. PubMed Scopus Google Scholar, Wisniewski H.M. Masters C.L. K. Acta Neuropathol. PubMed Scopus Google Scholar). with Congo red, Aβ fibrils In of the nonfibrillar Aβ the presence of aggregated but not fibrillar Aβ. with Congo red, the nonfibrillar Aβ was not of the Aβ fibrils were into the of an and for heparin In to was with the low of fibrillar Aβ the of the heparin that the was to a specific binding interaction and not to physical of the heparin by a of that the binding to Aβ fibrils could be by aggregated similar to that shown in E. measure binding from of several The results from were to the A.D. P. A to Scholar, R.T. A.D. 1991; PubMed Scopus Google Scholar), which an of this is in of of Aβ an of the results obtained by ACE, a binding was also of fibrillar or nonfibrillar Aβ were with in which the were to a membrane by and to measure the fibrillar but not Aβ bound heparin with a low affinity Congo red is a used for the of of all types in The binding of Congo red to Aβ has been postulated to in on fibrillar Aβ Abraham D.J. J. 1989; PubMed Scopus Google Scholar). We Congo red could the binding of heparin to fibrillar Aβ. of fibrillar were with of Congo red, and into the of an with the of Congo red and fibrils a dose-dependent of heparin binding to the fibrils was We also used the binding to the interaction of Congo red with fibrillar Aβ. In the an of binding is most readily the protein in the is high to the of heparin However, the binding were to a of Aβ to that the for Congo red of heparin binding with protein similar of Aβ were in the two a for Congo red than the may be to the of the Congo red of the well during the of in the the was from a or aggregated into fibrils as of were into the of and for binding The peptide not to heparin to peptide of fibrillar AβE22Q almost the of heparin of such as that in were and peptide of were as and results from several of fibrillar AβE22Q an of is in the low similar to the for heparin binding to wild type Aβ fibrils by the In Aβ was to a aggregation a in the heparin-binding of wild type and mutant In this peptide was for at at a of in and in the wild type Aβ in a binding state not However, the mutant peptide was to heparin and an affinity similar to that of AβE22Q We this as that AβE22Q a similar to that of wild type Aβ that been aggregated in with for the presence of this conformation from the that the interaction of heparin with the AβE22Q was by Congo red in a dose-dependent In addition, the ability of these to heparin was by incubation in for and is a solvent that is to or A. M. 1992; Scopus Google Scholar), and that can also the of fibrillar Aβ in D. J. 1993; PubMed Google Scholar). The presence of heparan sulfate has been immunohistochemically in amyloid deposits from most human diseases (for review, see A.D. Wight T.N. Neurobiol. Aging. 1989; 10: 481-497Crossref PubMed Scopus (188) Google Scholar). well is the amyloid of type L. Narindrasorasak S. R. Kisilevsky R. Arch. Pathol. Lab. 1992; Google Scholar). In this the amyloid protein, amylin, is the major constituent of the extracellular amyloid deposits that In the human of readily fibrils that are to A. B. Nature. 1994; PubMed Scopus Google Scholar). However, the amino acid in the both its into fibrils and its A. B. Nature. 1994; PubMed Scopus Google Scholar). We used to the heparin-binding properties of the human and of was in from of binding to human and are shown in bound to heparin at peptide as low as not to heparin even at obtained from two and results not the human was Congo red its aggregation and Congo red the interaction in a dose-dependent and the heparin-binding could be by at low Heparan sulfate proteoglycans are and components of parenchymal and vascular amyloid deposits in Alzheimer's disease and other However, of the binding interaction between and Aβ has been hindered by the unique difficulties of working with Aβ, a 40–42-residue peptide that readily precipitates into insoluble aggregates in vitro. and fibrils of Aβ have properties and are to have in AD methods used to study the interaction of Aβ and as as the aggregation state of the Aβ In this have used in at and to binding and its dependence on Aβ primary and of the primary amino acid sequence of Aβ that the for a heparin-binding where is a A.D. 1989; PubMed Google Scholar). However, from to nonfibrillar that in the of nonfibrillar Aβ, is an heparin-binding (20Brunden K.R. Richter-Cook N.J. Chaturvedi N. Frederickson R.C.A. J. Neurochem. 1993; 61: 2147-2154Crossref PubMed Scopus (121) Google Scholar) a similar by that the synthetic not to a heparin affinity at In to nonfibrillar Aβ, fibrillar Aβ readily bound to ACE, that the affinity of heparin for wild type fibrils is in the low this was the of Aβ as by amino acid a on the of fibrils a The of monomers is and is highly in a monomers with a of have of in of results to be consistent with of R. Frederickson R.C.A. K.R. J. 1995; Full Text Full Text PDF PubMed Scopus Google Scholar). We used low molecular heparin in of binding to Aβ fibrils to the of the heparin heparin of molecular may to the region on a heparin for used formed Aβ fibrils to of heparin on Aβ aggregation and to measure the binding affinity of heparin for a of Aβ. the of in the of Aβ J.D. Full Text PDF PubMed Scopus Google Scholar, A. Teplow D.B. J. Full Text Full Text PDF PubMed Scopus Google Scholar), it is to the heparin-binding properties of Aβ low molecular and other We the that HSPGs their heparan sulfate may to one or more of these a for further Aβ The specific amino on the of amyloid fibrils that the interaction to be In the of fibrillar Aβ, the an Aβ a conformation that it to from Aβ monomers that are on the may the heparin-binding of proteins in which heparin-binding are formed from by protein or type and factor in Ref. A.D. 1994; Full Text PDF PubMed Scopus Google Scholar). The of mutant Aβ in the basement of meningeal and cerebral blood vessels in to that this mutant Aβ have a affinity for vascular basement membrane the one from the which could its binding to by ACE, the heparin-binding properties of the mutant peptide were similar to of wild type peptide for both the fibrillar and nonfibrillar the mutant AβE22Q demonstrate that the mutant peptide a heparin-binding conformation more readily than the wild finding is consistent with which the ability of AβE22Q to in T. J. Frangione B. Biochem. Biophys. Res. 1991; PubMed Scopus Google Scholar, H. Selkoe D.J. Podlisny M.B. 1992; PubMed Scopus Google Scholar, A. D. 1993; PubMed Scopus Google Scholar, H. L. Biochem. Biophys. Res. 1993; PubMed Scopus Google Scholar). of as a for the Congo red the and incubation of AβE22Q in the solvent its ability to is the major protein of amyloid deposits in patients with type A. B. Nature. 1994; PubMed Scopus Google Scholar) that human formed and was to of The amino acid in the of of and that in of and both the formation and of A. B. Nature. 1994; PubMed Scopus Google Scholar). Because HSPGs have been detected immunohistochemically in the amyloid deposits of type L. Narindrasorasak S. R. Kisilevsky R. Arch. Pathol. Lab. 1992; Google Scholar), the binding of to the of a heparin-binding sequence Ref. A.D. 1989; PubMed Google Scholar), human from two bound to In to Aβ, found that human bound to heparin may be to a heparin-binding more to the strong tendency of human to an insoluble conformation in The ability of Congo red to the the of the heparin-binding by low and the of heparin binding by all the hypothesis. In Alzheimer's the of Aβ binding to HSPGs could from and R. Frederickson R.C.A. K.R. J. 1995; Full Text Full Text PDF PubMed Scopus Google Scholar, A.D. Sekiguchi P. Kimata K. A. M. 1994; Full Text PDF PubMed Scopus Google Scholar), of a for further Aβ deposition. proteoglycans may also play a role in the of Aβ M.D. R. Frederickson S.G. K.R. Neurobiol. Aging. 1995; PubMed Scopus Google Scholar). These various the that of the interaction could be a of therapeutic in Congo red is to the of Aβ M.D. R. Frederickson S.G. K.R. Neurobiol. Aging. 1995; PubMed Scopus Google Scholar, Y. K. Neurobiol. Aging. 1996; Google Scholar), and have shown that Congo red also Aβ binding to Congo red that are to the the of aggregated Aβ as well as the formation or of Aβ a it be to Congo red the of cerebral and AD in a of Alzheimer's disease D. D. R. R. P. C. T. J. T. F. T. S. K. K. M. P. Lieberburg I. S. E. L. M. L. L. E. Power M. Schenk D. P. B. F. H. J. S. B. J. 1995; Scholar, K. P. S. C. Y. S. F. G. Science. 1996; PubMed Scopus Google Scholar). of other small or were highly in the of in an R. 1995; PubMed Scopus Google Scholar), this the major of brain is A.D. J.K. Neurobiol. 1996; 3: Google Scholar), a by many of that both and perlecan can fibrillar Aβ in J. A. D. and D. J. In to both to the of the heparin-binding conformation of Aβ as well as to more characterize the binding of HSPGs such as and perlecan to fibrillar and nonfibrillar Aβ. We for on the and and of for with the binding assay.